Mesothelioma


Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 03/02/2020)

1ste line
BEAT (ETOP)
A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma.


2nd line 
Currently no trials